This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
        • Health Policy
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology
  4. Bladder Cancer

Conferences

Recent Abstracts
ASCO GU 2023: Genomic Alterations in Patients with Prostate Cancer with Liver Metastases February 17, 2023
ASCO GU 2023: Study of Real-World Treatment Patterns and Adherence to Bacillus Calmette-Guerin (BCG) in the Context of Guideline Recommendations for Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) February 17, 2023
ASCO GU 2023: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer February 17, 2023
ASCO GU 2023: A SEER-Medicare Based Quality Score for Patients with Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma and Its Association with Cost of Care and Survival February 17, 2023
ASCO GU 2023: Early Outcomes from Lutetium Lu-177 Vipivotide Tetraxetan Treatment in Patients Selected for Therapy with Piflufolastat F-18 PET Imaging February 17, 2023
ASCO GU 2023: A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (Interim Analysis) February 17, 2023
ASCO GU 2023: Chemotherapy, Immunotherapy, or Combination First-Line Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Large Real-World Experience February 17, 2023
ASCO GU 2023: SunRISe-4: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy February 17, 2023
ASCO GU 2023: Phase 2 KEYNOTE-057 Cohort C: Pembrolizumab with Vibostolimab or Favezelimab for Patients with High-Risk Bacillus Calmette-Guérin (BCG)-Unresponsive Non–muscle-Invasive Bladder Cancer (NMIBC) February 17, 2023
ASCO GU 2023: Phase 3 KEYNOTE-905/EV-303: Perioperative Pembrolizumab (Pembro) or Pembro + Enfortumab Vedotin for Muscle-Invasive Bladder Cancer (MIBC) February 17, 2023
ASCO GU 2023: Racial and Geographical Disparities in Pivotal Bladder Cancer Clinical Trials February 17, 2023
ASCO GU 2023: A Phase 1, Open-Label Trial to Evaluate Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle–invasive Bladder Cancer (NMIBC) February 17, 2023
ASCO GU 2023: Oncologic Outcomes in Patients with Residual Invasive Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy February 17, 2023
ASCO GU 2023: Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment-Weighted Analysis February 17, 2023
ASCO GU 2023: Use of a Navigable Interface for Integrated Whole Genome and Transcriptome Sequencing as a Platform for Pursuit of Therapeutic Targets in Advanced Prostate Cancers February 17, 2023
ASCO GU 2023: The Impact of Genomic Biomarkers on a Validated Clinical Risk Prediction Model for Upgrading/upstaging Among Men with Low-Risk Prostate Cancer February 17, 2023
ASCO GU 2023: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer (HCRN GU14-188) February 17, 2023
ASCO GU 2023: Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC) February 17, 2023
ASCO GU 2023: Ability of STAR-CAP Staging System to Prognosticate Risk of Subsequent Therapies After Initial Treatment of M0 Prostate Cancer February 17, 2023
ASCO GU 2023: Cell-Free Urinary Tumor DNA to Detect Minimal Residual Disease Prior to Repeat-Transurethral Resection of Bladder Tumor in Non–muscle-Invasive Bladder Cancer: A Prospective Study February 17, 2023
Page 10 of 507
  • Start
  • Prev
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free